ClinicalTrials.gg
CompletedNCT00320359Updated Mar 1, 2017

Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer

A Phase 3 interventional study of Intravenous topotecan/cisplatin and Intravenous etoposide/cisplatin in Lung Cancer, Small Cell, sponsored by GlaxoSmithKline. Completed at 79 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-01.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing topotecan in Small Cell Lung Carcinoma — 2 open to participants now, 4 under way, 2 of them phase 3. Topotecan · Small Cell Lung Carcinoma.

Enrollment
3rd of 28
700 · median 44
Started
2002
with 1 other
Phase 3
7 of 29
1 open now
Registered
17th of 29
by date
Lead sponsor
7 of 29
GlaxoSmithKline

Among the 29 studies testing topotecan in Small Cell Lung Carcinoma, this one is the 3rd largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2002, is one of 7 in phase 3, and was the 17th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 29 studies testing topotecan in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About topotecan

Topotecan: first FDA approval 1996 (HYCAMTIN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing topotecan in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

Evaluation of intravenous Topotecan + Cisplatin as a potential new standard of care in 1st line Small Cell Lung Cancer

03

Conditions studied

  • Lung Cancer, Small Cell

Keywords

  • First-line Cisplatin
  • Small Cell Lung Cancer
  • topotecan
  • etoposide
  • Extensive Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evaluable extensive small cell lung cancer, extensive disease.
  • (ECOG) performance status \< 2.
  • > 3 months.
  • Fit to receive any of the treatments.
  • No prior chemotherapy.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Extensive disease treatable with radiotherapy.
  • Past or current history of other malignant disease.
  • Prior chemotherapy.
  • Pregnancy, lactating or lack of effective .
  • Concurrent severe medical problems other than small cell lung cancer.
  • Patients with central nervous system receiving more than 12 mg /day dexamethasone or equivalent to control symptoms.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
700 participants (actual)

Study arms

  • Active comparator
    Arm A

    Cisplatin 75 mg/m2 i.v., day 1, Etoposide 100 mg/m2 i.v., days 1-3

    Drug: Intravenous etoposide/cisplatin

  • Experimental
    Arm B

    Topotecan 1 mg/ m2, i.v., days 1-5 Cisplatin 75 mg/m2 i.v., days 5

    Drug: Intravenous topotecan/cisplatin

Interventions

  • DrugIntravenous topotecan/cisplatin

    Drug pages: Topotecan · Cisplatin

    Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5. Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan.

  • DrugIntravenous etoposide/cisplatin

    Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid. Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3.

06

What researchers measure

Primary outcomes

  1. Median overall survival time of participants

    Time frame: Up to 1 year after randomization of the last patient

Secondary outcomes

  1. Number of participants with one year survival rate of the participants

    Time frame: Up to 1 year after randomization of the last patient

  2. Median time of disease progression

    Time frame: up to 1 year after randomization of the last patient

  3. Median time to event (progressive disease or death) of participants

    Time frame: Up to 1 year after randomization of the last patient

  4. Median time to response to chemotherapy

    Time frame: Up to 1 year after randomization of the last patient

  5. Median response duration

    Time frame: Up to 1 year after randomization of the last patient

  6. Number of participants with objective response

    Time frame: Up to 1 year after randomization of the last patient

  7. Mean lung cancer symptom score (LCSS)

    Time frame: Up to 18 weeks

  8. Mean eastern cooperative oncology group (ECOG) score

    Time frame: Up to 18 weeks

  9. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to 1 year after randomization of the last patient

  10. Mean change from Baseline in hemoglobin value

    Time frame: Baseline and up to 18 weeks

  11. Mean change from Baseline in leukocytes, neutrophils and platelets count

    Time frame: Baseline and up to 18 weeks

  12. Mean change from Baseline in red blood cells (RBCs)

    Time frame: Baseline and up to 18 weeks

  13. Mean change from Baseline in Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase and Lactate dehydrogenase (LDH)

    Time frame: Baseline and up to 18 weeks

  14. Mean change from Baseline in Blood urea nitrogen (BUN), Potassium, Sodium and urea

    Time frame: Baseline and up to 18 weeks

  15. Mean change from Baseline in Creatinine and Total bilirubin

    Time frame: Baseline and up to 18 weeks

  16. Mean change from Baseline in Creatinine clearance

  17. Mean change from Baseline in total protein

    Time frame: Baseline and up to 18 weeks

  18. Number of participants with abnormal urinalysis results

  19. Mean change from Baseline in weight

    Time frame: Baseline and up to 18 weeks

  20. Mean change from Baseline in Body surface area

    Time frame: Baseline and up to 18 weeks

07

Study locations

79 sites
  • GSK Investigational Site
    Bludesch, A-6719, Austria
  • GSK Investigational Site
    Klagenfurt, A-9020, Austria
  • GSK Investigational Site
    Linz, A-4020, Austria
  • GSK Investigational Site
    Vienna, A-1140, Austria
  • GSK Investigational Site
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • GSK Investigational Site
    Karlsruhe, Baden-Wuerttemberg 76137, Germany
  • GSK Investigational Site
    Loewenstein, Baden-Wuerttemberg 74245, Germany
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68167, Germany
  • GSK Investigational Site
    Wangen, Baden-Wuerttemberg 88239, Germany
  • GSK Investigational Site
    Bayreuth, Bayern 95445, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80336, Germany
  • GSK Investigational Site
    Nuernberg, Bayern 90340, Germany
  • GSK Investigational Site
    Passau, Bayern 94032, Germany
  • GSK Investigational Site
    Regensburg, Bayern 93049, Germany
  • GSK Investigational Site
    Rosenheim, Bayern 83022, Germany
  • GSK Investigational Site
    Cottbus, Brandenburg 03048, Germany
  • GSK Investigational Site
    Frankfurt/Oder, Brandenburg 15236, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60431, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 65929, Germany
  • GSK Investigational Site
    Giessen, Hessen 35392, Germany
  • GSK Investigational Site
    Greifenstein, Hessen 35753, Germany
  • GSK Investigational Site
    Kassel, Hessen 34125, Germany
  • GSK Investigational Site
    Limburg, Hessen 65549, Germany
  • GSK Investigational Site
    Marburg, Hessen 35043, Germany
  • GSK Investigational Site
    Offenbach, Hessen 63069, Germany
  • GSK Investigational Site
    Wiesbaden, Hessen 65199, Germany
  • GSK Investigational Site
    Greifswald, Mecklenburg-Vorpommern 17487, Germany
  • GSK Investigational Site
    Neubrandenburg, Mecklenburg-Vorpommern 17036, Germany
  • GSK Investigational Site
    Rostock, Mecklenburg-Vorpommern 18057, Germany
  • GSK Investigational Site
    Rostock, Mecklenburg-Vorpommern 18059, Germany
  • GSK Investigational Site
    Stralsund, Mecklenburg-Vorpommern 18437, Germany
  • GSK Investigational Site
    Waren, Mecklenburg-Vorpommern 17192, Germany
  • GSK Investigational Site
    Goettingen, Niedersachsen 37075, Germany
  • GSK Investigational Site
    Leer, Niedersachsen 26789, Germany
  • GSK Investigational Site
    Stade, Niedersachsen 21680, Germany
  • GSK Investigational Site
    Bielefeld, Nordrhein-Westfalen 33604, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44791, Germany
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53111, Germany
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53113, Germany
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53177, Germany
  • GSK Investigational Site
    Coesfeld, Nordrhein-Westfalen 48653, Germany
  • GSK Investigational Site
    Dorsten, Nordrhein-Westfalen 46282, Germany
  • GSK Investigational Site
    Duisburg, Nordrhein-Westfalen 47166, Germany
  • GSK Investigational Site
    Duisburg, Nordrhein-Westfalen 47228, Germany
  • GSK Investigational Site
    Hamm, Nordrhein-Westfalen 59071, Germany
  • GSK Investigational Site
    Hemer, Nordrhein-Westfalen 58675, Germany
  • GSK Investigational Site
    Herne, Nordrhein-Westfalen 44625, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 50924, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 50931, Germany
  • GSK Investigational Site
    Krefeld, Nordrhein-Westfalen 47798, Germany
  • GSK Investigational Site
    Oberhausen, Nordrhein-Westfalen 46145, Germany
  • GSK Investigational Site
    Velbert, Nordrhein-Westfalen 42551, Germany
  • GSK Investigational Site
    Wuppertal, Nordrhein-Westfalen 42283, Germany
  • GSK Investigational Site
    Koblenz, Rheinland-Pfalz 56073, Germany
  • GSK Investigational Site
    Ludwigshafen, Rheinland-Pfalz 67063, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Trier, Rheinland-Pfalz 54290, Germany
  • GSK Investigational Site
    Halle/Saale, Sachsen-Anhalt 06114, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39120, Germany
  • GSK Investigational Site
    Chemnitz, Sachsen 09113, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04207, Germany
  • GSK Investigational Site
    Plauen, Sachsen 08529, Germany
  • GSK Investigational Site
    Borstel, Schleswig-Holstein 23845, Germany
  • GSK Investigational Site
    Flensburg, Schleswig-Holstein 24939, Germany
  • GSK Investigational Site
    Grosshansdorf, Schleswig-Holstein 22927, Germany
  • GSK Investigational Site
    Erfurt, Thueringen 99089, Germany
  • GSK Investigational Site
    Jena, Thueringen 07747, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 12200, Germany
  • GSK Investigational Site
    Berlin, 12559, Germany
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Berlin, 13585, Germany
  • GSK Investigational Site
    Berlin, 14089, Germany
  • GSK Investigational Site
    Berlin, 14109, Germany
  • GSK Investigational Site
    Bremen, 28325, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Hamburg, 21075, Germany
  • GSK Investigational Site
    Hamburg, 22043, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2006
First posted
May 3, 2006
Start
Aug 2002
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Last update
Mar 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00320359
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 3, 2006
Start date
Aug 2002
Primary completion
Feb 2007
Completion
Feb 2007
Last update
Mar 1, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Topotecan · Cisplatin

Start the discussion